- Home
- BTMD vs PMVP Comparison
BTMD vs PMVP Comparison
Compare BTMD & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTMD | PMVP |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.4M | 66.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BTMD | PMVP |
|---|---|---|
| Price | $2.45 | $1.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $6.00 | $5.00 |
| AVG Volume (30 Days) | 124.9K | ★ 263.3K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 270.48 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $195,645,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.80 | N/A |
| P/E Ratio | $3.34 | ★ N/A |
| Revenue Growth | ★ 1.34 | N/A |
| 52 Week Low | $2.32 | $0.81 |
| 52 Week High | $6.36 | $1.84 |
Technical Indicators
Market Signals| Indicator | BTMD | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 38.59 | 46.85 |
| Support Level | $2.56 | $1.21 |
| Resistance Level | $2.80 | $1.27 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 1.14 | 66.67 |
Price Performance
Historical ComparisonAbout BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.